KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Cash & Equivalents (2018 - 2025)

Historic Cash & Equivalents for Aurinia Pharmaceuticals (AUPH) over the last 10 years, with Q3 2025 value amounting to $73.2 million.

  • Aurinia Pharmaceuticals' Cash & Equivalents rose 9705.19% to $73.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $73.2 million, marking a year-over-year increase of 9705.19%. This contributed to the annual value of $83.4 million for FY2024, which is 7070.69% up from last year.
  • Latest data reveals that Aurinia Pharmaceuticals reported Cash & Equivalents of $73.2 million as of Q3 2025, which was up 9705.19% from $53.0 million recorded in Q2 2025.
  • Aurinia Pharmaceuticals' 5-year Cash & Equivalents high stood at $231.9 million for Q4 2021, and its period low was $33.4 million during Q2 2024.
  • Over the past 5 years, Aurinia Pharmaceuticals' median Cash & Equivalents value was $81.7 million (recorded in 2023), while the average stood at $90.0 million.
  • Per our database at Business Quant, Aurinia Pharmaceuticals' Cash & Equivalents plummeted by 7685.02% in 2021 and then soared by 9705.19% in 2025.
  • Over the past 5 years, Aurinia Pharmaceuticals' Cash & Equivalents (Quarter) stood at $231.9 million in 2021, then crashed by 59.39% to $94.2 million in 2022, then tumbled by 48.1% to $48.9 million in 2023, then surged by 70.71% to $83.4 million in 2024, then fell by 12.28% to $73.2 million in 2025.
  • Its Cash & Equivalents was $73.2 million in Q3 2025, compared to $53.0 million in Q2 2025 and $66.4 million in Q1 2025.